We are proud to announce that one of our SUL-compounds, SUL-121, is proven to have both an anti-inflammatory and bronchodilating effect in vitro and in vivo. In the study, performed by the University of Groningen, the researchers explored the anti-inflammatory and bronchodilating properties of the novel pharmacological compound SUL-121 in vitro and in vivo. Their conclusion is that SUL-121 can be a novel approach for treating the major burden disease COPD. The poster with the data were presented last May on the American Thorac Society (ATS2015) conference in Denver, Colorado.
COPD is a worldwide growing major health issue
Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem. According to the WHO COPD is an under-diagnosed, life threatening lung disease that may progressively lead to death. COPD is characterized by airway obstruction and chronic inflammation. Although most patients can be treated with (combinations of) bronchodilating agents and anti-inflammatory glucocorticosteroids, a subset of patients responds poorly to these drugs leading to increased hospitalizations.
A new class of chemicals with major potential
SUL-121 is one of the new class of chemicals based on the protective effects of nature’s hibernation mechanism that have been developed by Sulfateq. These so-called SUL-compounds show a great potential in therapeutic application for human medicine. The SUL-compounds have been tested in animal models with prove of concept for the protection of cells, tissues and organs. Sulfateq B.V. has not only identified applications of the SUL-compounds in Chronic Obstructive Pulmonary Disease (COPD), but also for Acute Kidney Injury (AKI) and Obesity/Diabetes II.
If you are interested in the applications of the SUL-compounds please visit our website.